Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q2 2015 Earnings Presentation
26 slides from Chugai Pharmaceutical's earnings presentation, Jul 23, 2015
Slide 1: FY2015 2Q Consolidated Financial Overview (IFRS based)
FY2015 2Q Consolidated Financial Overview (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President, CFO Yoshio Itaya July 23, 2015
Slide 2: Forward-Looking Statements
FY2015 2Q Consolidated Financial Overview Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information a
Slide 3: 2Q Results Summary
FY2015 2Q Consolidated Financial Overview 2Q Results Summary Revenues: 240.2 billion yen (+18.2, +8.2% YoY) • Domestic sales excl. Tamiflu: increase due to steady growth of mainstay products and new products (+13.8, +8.3%) • Overseas sales: increase due to growth in Actemra export driven by both y
Slide 4: IFRS and Core Results Jan – Jun
FY2015 2Q Consolidated Financial Overview IFRS and Core Results Jan – Jun IFRS results Non-core items Core results (Billions of JPY) (Billions of JPY) 2015 Intangible assets Other 2015 Non-Core items and Business eliminated 1. Intangible/Business combinations Jan - Jun combinations items Jan - Jun A
Slide 5: Financial Overview Jan – Jun
FY2015 2Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan – Jun 2014 2015 (Billions of JPY) Jan - Jun Jan - Jun Growth (Billions of JPY) vs. Revenues vs. Revenues Revenues 222.0 240.2 +18.2 +8.2% Royalties and other operating income -6.4 Sales 208.1 232.6 +24.5 +11.8% decr
Slide 6: Sales (excl. Tamiflu) Jan – Jun
FY2015 2Q Consolidated Financial Overview Year on Year Sales (excl. Tamiflu) Jan – Jun Sales by Disease Area, Sales by Products, Year on Year Comparisons Year on Year Changes (Billions of JPY) +24.9, +12.4% 225.9 201.0 -2.4 Pegasys Actemra +11.2 Overseas (1.3) (overseas) 46.8 (37.7) +11.1, +31.1% Co
Slide 7: Tamiflu Sales Performance
FY2015 2Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales Forecast (Billions of JPY) FY2009.12 FY2010.12 FY2011.12 FY2012.12 FY2013.12 FY2014.12 FY2015.12 Cases per Seasonal sentinel* Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun
Slide 8: Operating Profit Jan – Jun
FY2015 2Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan – Jun (Billions of JPY) 2014 2015 (Billions of JPY) Growth Jan - Jun Jan - Jun Revenues 222.0 240.2 +18.2 Royalties and other operating income Cost of sales -102.1 -116.6 -14.5 Gross profit -6.4 Gross profit 119.9 123
Slide 9: Financial Overview Apr – Jun
FY2015 2Q Consolidated Financial Overview Year on Year (Core) Financial Overview Apr – Jun 2014 2015 (Billions of JPY) Apr - Jun Apr - Jun Growth (Billions of JPY) vs. Revenues vs. Revenues Revenues 98.0 123.1 +25.1 +25.6% Increase in gross profit from sales +13.0 Sales 93.9 119.2 +25.3 +26.9% Incre
Slide 10: Financial Progress Jan – Jun
FY2015 2Q Consolidated Financial Overview vs. Forecast (Core) Financial Progress Jan – Jun Actual Forecast on Jan 28 2014 (Billions of JPY) 2015 2015 Progress Progress * Jan - Jun Jan - Dec Revenues 240.2 486.5 49.4% 48.1% Sales 232.6 460.8 50.5% 47.6% excl. Tamiflu 225.9 453.4 49.8% 47.4% Domestic
Slide 11: Sales Progress (excl. Tamiflu) Jan – Jun
FY2015 2Q Consolidated Financial Overview vs. Forecast (Core) Sales Progress (excl. Tamiflu) Jan – Jun Actual Full-year forecast 2014 (Billions of JPY) 2015 2015 Progress Progress*1 Jan - Jun Jan - Dec Sales excl. Tamiflu 225.9 453.4 49.8% 47.4% Domestic 179.1 360.9 49.6% 47.3% Oncology 101.8 204.5
Slide 12: Impact from Foreign Exchange
FY2015 2Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange [Reference] FX impact Jan - Jun Historical exchange rate to the JPY (Billions of JPY) (vs. Forecast on Jan. 28) JPY +1.6 150 2015 EUR 2015 CHF 2014 EUR 2014 CHF 145 Revenues Sales +1.9 140 Royalties and other
Slide 13: Balance Sheet Items
FY2015 2Q Consolidated Financial Overview vs. 2014 Year End Balance Sheet Items < Assets, Liabilities, and Net Assets > (Billions of JPY) 2014 2015 (Billions of JPY) Change Decrease in net working capital -4.8 Dec Jun Trade accounts receivable 141.3 128.3 - 13.0 Decrease in trade accounts receivable
Slide 14: Net Cash
FY2015 2Q Consolidated Financial Overview vs. 2014 Year End Net Cash Total decrease in net working capital, etc. Total investment Operating cash flow after adjustments +52.1 +7.0 -13.8 (Billions of JPY) Operating profit +43.2 Others Depreciation and amortization, etc. +8.9 Operating cash flow after
Slide 15: Free Cash Flow Jan - June
FY2015 2Q Consolidated Financial Overview Year on Year Free Cash Flow Jan - June 2014 2015 (Billions of JPY) (Billions of JPY) Change Jan-Jun Jan-Jun Operating profit - IFRS basis 43.1 43.2 +0.1 Operating profit, net of operating cash adjustments +0.2 Depreciation and impairment of Property, plant a
Slide 16: Overview of Development Pipeline
Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President Yutaka Tanaka 2015.7.23
Slide 17: Oncology Field Projects under Development
Overview of Development Pipeline Oncology Field Projects under Development (as of 23 July, 2015) Phase I Phase II Phase III Filed CKI27 / RG7304 AF802 (RG7853) AF802 (RG7853) RG340 / Xeloda (Japan / overseas) / Alecensa (overseas) / Alecensa (overseas) - gastric cancer (adjuvant) - solid tumors - NS
Slide 18: Primary Field Projects under Development
Overview of Development Pipeline Primary Field Projects under Development (as of 23 July, 2015) Phase I Phase II Phase III Filed RG484 / Bonviva (oral) Bone & Joint - osteoporosis MRA / Actemra MRA / Actemra (overseas) - large-vessel vasculitis - systemic sclerosis - giant cell arteritis (overseas)
Slide 19: Development Status
Overview of Development Pipeline Development Status In- RG7446 / atezolizumab (Engineered anti-PDL1 antibody) licensed RG435 / Avastin® Renal cell carcinoma Started global P3 in June 2015 In- RG7440 / ipatasertib licensed Solid tumors Started P1 in June 2015 In- PCO371 house Hypoparathyroidism Start
Slide 20: Other Progress
Overview of Development Pipeline Other Progress In- MRA / Actemra® house Systemic sclerosis US FDA granted Breakthrough Therapy designation in June 2015 (Roche) Decided to participate in global P3 (Chugai) In- ACE910 house Hemophilia A Planned to start global P3 for “inhibitor” patients in 2015 Plan
Slide 21: Data Presentation at Scientific Meetings: AF802 / Alecensa
Overview of Development Pipeline Data Presentation at Scientific Meetings: AF802 / Alecensa® In- Presented P1/2 study data for ALK positive NSCLC at house American Society of Clinical Oncology (ASCO) in June 2015 Overseas P1/2 * Overseas P1/2 * Japanese P1/2 (Global) (North America) ORR 50% 47.8% 93
Slide 22: Data Presentation at Scientific Meetings: ACE910
Overview of Development Pipeline Data Presentation at Scientific Meetings: ACE910 In- Presented long-term treatment data in the Japanese P1/2 study for Hemophilia A at The house International Society on Thrombosis and Haemostasis in June 2015 - Once weekly SC administration of ACE910 was well tolera
Slide 23: RG7440 (AKT inhibitor): Mode of Action
Overview of Development Pipeline RG7440(AKT inhibitor): Mode of Action Growth factor AKT transmits intracellular receptors PIP2 PTEN PIP3 signaling from the receptor through PI3K-AKT-mTOR PI3K pathway PDK1 mTORC2 S473 P T308 P AKT is one of the most AKT frequently activated protein RG7440 kinase
Slide 24: Updates on the Development Requests for Unapproved Drugs/Indications
Overview of Development Pipeline Updates on the Development Requests for Unapproved Drugs/Indications Review Committee of Development Requests for Unapproved Drugs/Indication Ten indications (including additional dosages and administrations) of eight products from the first round requests have b
Slide 25: Projected Submissions (Post PoC NMEs and Products)
Overview of Development Pipeline Projected Submissions (Post PoC NMEs and Products) Seamless filings every year NME line extension in-house in-licensed ACE910 Hemophilia A BONVIVA lebrikizumab (RG484) (RG3637) Osteoporosis (oral) Asthma Filed in Feb. 2015 atezolizumab (RG7446) Bladder Cancer ACTEM
Slide 26: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp Koki Harada, Hiroshi Araki, Sachiyo Yoshimura, Chisato Miyoshi Investor Relations Group Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: ir@chugai-pharm
Chugai Pharmaceutical — Q2 2015 Earnings Presentation on 6ix